MBX MBX BIOSCIENCES INC.

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.

The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast  or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at /news-events/events.

About MBX Biosciences 

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at and follow it on .

Media Contact:

Katie Beach Oltsik

Inizio Evoke Comms



(937) 232-4889

Investor Contact:

Jim DeNike

MBX Biosciences



EN
19/09/2025

Underlying

MBXMBX BIOSCIENCES INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MBX BIOSCIENCES INC.

 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of P...

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) a...

September 19, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 f...

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced dosing of the first participant in its Phase 1 trial of MBX 4291, the Company’s Precision ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Reports Second Quarter 2025 Financial Results and Rece...

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million in cash, cash equivalents and marketable securities as of June 30, 2025; expected to support operations into mid-2027 CARMEL, Ind., Aug. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, I...

August 7, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice Presid...

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatide CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clin...

June 23, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting ...

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic dis...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch